Skip to content
Disclosery

Aisling Capital Management LP

Follow

13F filer, CIK 1766721, NEW YORK, NY

Aisling Capital Management LP reported $288,452,198 across 13 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-13. Its ten largest share positions make up 99.5% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001766721-25-000003

Period
2025-03-31
Reported value
$288M
Holdings
13
Top 10 weight
99.5%
New
0
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CMPSadded+233,918$669K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
VERONA PHARMA PLCreduced-500,000-$31.7M
POSEIDA THERAPEUTICS INCexited-1,043,267-$10M
VIRACTA THERAPEUTICS INCexited-288,571-$46.2K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0001766721-25-000003, largest first. % of portfolio is the value over $288,452,197, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,068,125 shares; 2024Q4: 6,068,125 shares; 2025Q1: 6,068,125 shares 6,068,125$210M72.72%0Timeline
VERONA PHARMA PLCVERONA PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,115,352 shares; 2024Q4: 1,115,352 shares; 2025Q1: 615,352 shares 615,352$39.1M13.54%-500,000
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,025,000 shares; 2024Q4: 1,025,000 shares; 2025Q1: 1,025,000 shares 1,025,000$12.6M4.36%0Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 568,919 shares; 2024Q4: 568,919 shares; 2025Q1: 568,919 shares 568,919$7.41M2.57%0Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,472,331 shares; 2024Q4: 1,472,331 shares; 2025Q1: 1,472,331 shares 1,472,331$6.83M2.37%0Timeline
NUVBNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,541,009 shares; 2024Q4: 2,541,009 shares; 2025Q1: 2,541,009 shares 2,541,009$4.47M1.55%0Timeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 964,500 shares; 2024Q4: 964,500 shares; 2025Q1: 1,198,418 shares 1,198,418$3.43M1.19%+233,918Timeline
BMEABIOMEA FUSION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 798,757 shares; 2024Q4: 798,757 shares; 2025Q1: 798,757 shares 798,757$1.7M0.59%0Timeline
CALCCALCIMEDICA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 521,114 shares; 2024Q4: 521,114 shares; 2025Q1: 521,114 shares 521,114$995K0.35%0Timeline
ELEVATION ONCOLOGY INC COMELEVATION ONCOLOGY INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,834,910 shares; 2024Q4: 2,834,910 shares; 2025Q1: 2,834,910 shares 2,834,910$735K0.25%0
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 434,455 shares; 2024Q4: 434,455 shares; 2025Q1: 434,455 shares 434,455$665K0.23%0Timeline
MRKRMARKER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 314,286 shares; 2024Q4: 325,370 shares; 2025Q1: 325,370 shares 325,370$400K0.14%0Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 88,607 shares; 2025Q1: 88,607 shares 88,607$381K0.13%0Timeline

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
POSEIDA THERAPEUTICS INCPOSEIDA THERAPEUTICS INC1,043,267$10Mshares
VIRACTA THERAPEUTICS INCVIRACTA THERAPEUTICS INC288,571$46.2Kshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001766721-25-000003 base2025-05-13acceptance time not in the bulk data set